Ventajas con el uso de Yondelis + PLD en pacientes seleccionados con cáncer de ovario recurrente sensible al platino incluyen tiempo adicional para recuperarse de toxicidades relacionadas con el platino, evitar reacciones de hipersensibilidad y el efecto de secuencia por el cual Yondelis puede mejorar la respuesta al siguiente Platino y prolongar la supervivencia .

Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.

Colombo N, et al. Expert Rev Anticancer Ther. 2016.

Abstract

INTRODUCTION:

 As most patients with ovarian cancer experience multiple remissions and relapses, oncologists must prepare ahead for long-term treatment. While platinum-based regimens are standard of care for platinum-sensitive recurrence, there are circumstances in which platinum rechallenge is not the best approach. These situations include patients with limited sensitivity to platinum; patients with residual toxicity from previous platinum therapy; and patients at risk of developing hypersensitivity reactions. An alternative regimen for these patients is the non-platinum combination of trabectedin + pegylated liposomal doxorubicin (PLD). Areas covered: In this review, case studies are presented to illustrate how careful strategic planning, in terms of therapeutic choices and optimal sequencing, can achieve good outcomes in difficult-to-treat patients. Expert commentary: Advantages with use of trabectedin + PLD in selected patients with platinum-sensitive recurrent ovarian cancer include additional time to recover from platinum-related toxicities, avoidance of hypersensitivity reactions, and the 'sequence effect' by which trabectedin may enhance response to next platinum and prolong survival.

Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin.

González-Martín A, et al. Expert Rev Anticancer Ther. 2016.

Abstract

INTRODUCTION:

 Given the heterogeneity of both disease and clinical situation, recurrent ovarian cancer continues to be a considerable therapeutic challenge. While newer treatment options have led to improved clinical outcomes, treatment selection has become more complex. An increasing number of clinical questions must be addressed before the optimal strategy and sequence can be decided for an individual patient. Areas covered: In this review, evidence is examined to guide decision-making for the main treatment options of surgery, chemotherapy and targeted therapy. Expert commentary: For each option, the same set of patient- and tumor-related factors can be used to identify appropriate candidates. Over the next few years, results of ongoing randomized studies are expected to shed light on several unresolved issues in the treatment of recurrent ovarian cancer.